Tag: CTX310
-
First-in-Human Gene-Editing Therapy Halves Bad Cholesterol: CTX310 Trial Signals Breakthrough
Groundbreaking CTX310 Trial in Australia Shows Promise for Hard-to-Treat Lipid Disorders In a landmark study conducted in Australia, researchers have reported that a first-in-human trial of CTX310—a gene-editing therapy—effectively halves levels of low-density lipoprotein (LDL) cholesterol and triglycerides in individuals with lipid disorders that are difficult to manage with current treatments. The early results, unveiled…
-
First-in-Human Trial: CTX310 Gene-Editing Therapy Halves Bad Cholesterol
Groundbreaking Step in Lipid Disorder Treatment In a landmark development for cardiovascular health, researchers in Australia have initiated a first-in-human trial of CTX310, a gene-editing therapy designed to dramatically reduce bad cholesterol (LDL) and triglycerides in individuals with difficult-to-treat lipid disorders. Early results suggest the therapy can halve levels of harmful lipids, offering a potential…
-
Time gene editing therapy to halve bad cholesterol: Australia leads first-in-human trial
Groundbreaking first-in-human trial unfolds in Australia Researchers in Melbourne have announced a landmark first-in-human trial of a gene-editing therapy aimed at drastically reducing harmful lipids in the blood. The study tests CTX310, a pioneering treatment designed for people with difficult-to-treat lipid disorders who struggle to control their LDL cholesterol and triglyceride levels despite standard therapies.…